By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Alza
Corp. et al. v. Par Pharmaceutical Inc. et al.
1:13-cv-01104;
filed June 19, 2013 in the District Court of Delaware

• Plaintiffs: 
Alza Corp.; Janssen Pharmaceuticals Inc.
• Defendants: 
Par Pharmaceutical Inc.; Actavis Elizabeth LLC; Actavis Inc.

Infringement
of U.S. Patent No. 8,163,798 ("Methods and Devices for Providing Prolonged
Drug Therapy," issued April 24, 2012) following a Paragraph IV
certification as part of Par's filing of an ANDA to manufacture a generic
version of Alza's Concerta® (methylphenidate hydrochloride, used to treat
attention deficit hyperactivity disorder). 
View the complaint here.

Kissei
Pharmaceutical Co. Ltd. et al. v. Hetero USA Inc., et al.
1:13-cv-01091;
filed June 17, 2013 in the District Court of Delaware

• Plaintiffs: 
Kissei Pharmaceutical Co. Ltd.; Watson Laboratories Inc.; Actavis Inc.
• Defendant:  Sandoz
Inc.

Kissei
Pharmaceutical Co. Ltd. et al. v. Sandoz Inc.
1:13-cv-01092;
filed June 17, 2013 in the District Court of Delaware

• Plaintiffs: 
Kissei Pharmaceutical Co. Ltd.; Watson Laboratories Inc.; Actavis Inc.
• Defendants: 
Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Ltd., Unit III

The
complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 5,387,603 ("1,5,7-Trisubstituted
Indoline Compounds and Salts Thereof," issued February 7, 1995) following
a Paragraph IV certification as part of Hetero's filing of an ANDA to
manufacture a generic version of Watson's Rapaflo® (silodosin, used to treat benign
prostatic hyperplasia).  View the Hetero complaint here.

AbbVie Inc.
v. Mylan Pharmaceuticals Inc.
1:13-cv-01072;
filed June 14, 2013 in the District Court of Delaware

Infringement
of U.S. Patent Nos. 6,232,333 ("Pharmaceutical Composition," issued
May 15, 2001), 7,141,593 ("Pharmaceutical Formulations," issued
November 28, 2006), and 7,432,294 (same title, issued October 7, 2008)
following a Paragraph IV certification as part of Mylan's filing of an ANDA to
manufacture a generic version of AbbVie's Norvir® (ritonavir, used to treat
human immunodeficiency virus (HIV) infection). 
View the complaint here.

Insite Vision
Inc. et al. v. Mylan Pharmaceuticals Inc. et al.
3:13-cv-03720;
filed June 14, 2013 in the District Court of New Jersey

• Plaintiffs: 
Insite Vision Inc.; Merck Sharp & Dohme Corp.; Inspire
Pharmaceuticals, Inc.; Pfizer Inc.
• Defendants: 
Mylan Pharmaceuticals Inc.; Mylan Inc.

Infringement
of U.S. Patent Nos. 6,861,411 ("Method of Treating Eye Infections with
Azithromycin," issued March 1, 2001), 6,239,113 ("Topical Treatment
or Prevention of Ocular Infections," issued May 29, 2001), 6,569,443 (same
title, issued May 27, 2003), and 7,056,893 (same title, issued June 6, 2006),
licensed to Inspire (now Merck), following a Paragraph IV certification as part
of Mylan's filing of an ANDA to manufacture a generic version of Merck's
AzaSite® (azithromycin, used to treat bacterial conjunctivitis).  View the complaint here.

Senju
Pharmaceutical Co., Ltd v. Apotex Inc. et al.
1:13-cv-04132;
filed June 14, 2013 in the Southern District of New York

• Plaintiff: 
Senju Pharmaceutical Co., Ltd.
• Defendants: 
Apotex Inc.; Apotex Corp.; Ista Pharmaceuticals, Inc; Bausch & Lomb
Inc.

Infringement
of U.S. Patent No. 6,335,335 ("Prolonged-Action Eye Drop," issued
January 1, 2002) following a Paragraph IV certification as part of Apotex's
filing of an ANDA to manufacture a generic version of Senju's Istalol® (timolol
maleate ophthalmic solution, 0.5%, used treat elevated intraocular pressure in
patients with ocular hypertension or open-angle glaucoma).  View the complaint here.